Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)

Ohe, Yuichiro; ...; Andric, Zoran G; ...; (broj, koautora 17)

Results

eNauka > Results > Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)

Title:	Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)
Authors:	Ohe, Yuichiro; ...; Andric, Zoran G ; ...; (broj, koautora 17)
Issue Date:	2022
Publication:	CANCER RESEARCH
ISSN:	0008-5472 Cancer Research Search Idenfier
Type:	Conference Paper
Collation:	vol. 82 br. 12
WoS-ID:	000892509500073
URI:	https://enauka.gov.rs/handle/123456789/819383
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

Find the DOI

Finding a DOI in CrossRef based on publication meta-data. The DOI (and metadata) with the similar data match will be displayed. ATTENTION - it doesn't have to be that publication.

Google Scholar^TM